<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features and diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features and diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features and diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen J Gluckman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony L Komaroff, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is an illness of uncertain cause. While underlying objective findings involving the central and autonomic nervous systems, the immune system, and energy metabolism have been described, these objective abnormalities have not yet led to a clear understanding of pathophysiology or to a diagnostic test of adequate sensitivity and specificity [<a href="#rid1">1</a>].</p><p>The condition has long been recognized, and many different terms have been used to describe it (eg, DaCosta's syndrome, effort syndrome, soldier's heart, neurasthenia, myalgic encephalitis/encephalomyelitis, Iceland disease, Akureyri disease, Royal Free disease, and chronic fatigue and immune dysfunction syndrome) [<a href="#rid2">2,3</a>].</p><p>The clinical manifestations and diagnosis of CFS are reviewed here. The general approach to a patient with fatigue and the treatment of CFS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a> and  <a class="medical medical_review" href="/z/d/html/2742.html" rel="external">"Treatment of myalgic encephalomyelitis/chronic fatigue syndrome"</a>.)</p><p class="headingAnchor" id="H17480707"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>There are multiple case definitions for CFS, and these have changed over time [<a href="#rid4">4-9</a>]. The Institute of Medicine (IOM; now known as the National Academy of Science) diagnostic criteria focus on the most specific features of the disease. As with previous definitions, symptoms should be present for at least six months and have moderate, substantial, or severe intensity at least one-half of the time. In addition to fatigue, other criteria include: post-exertional malaise, unrefreshing sleep, cognitive impairment, and orthostatic-related symptoms.</p><p>These clinical case definitions are standard epidemiologic tools employed when there is no diagnostic test for a specific disorder. They are "intentionally restrictive, to maximize the chances that research studies will detect significant associations if such associations truly exist" [<a href="#rid7">7</a>]. Although a clinical case definition is a well-established instrument, its strict application may not always be appropriate in the evaluation of a specific patient.</p><p class="headingAnchor" id="H4"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>While fatigue is a very common presenting complaint in primary care practice, patients meeting formal case definitions of CFS are unusual. The prevalence of CFS is uncertain, in part due to difficulties in establishing the diagnosis; however, using the clinical case definition allows for some estimates. In one study of 1000 consecutive patients in a primary care clinic, for example, 8.5 percent had debilitating fatigue of at least six months' duration without apparent cause; however, only 15 percent of these patients satisfied the clinical definition for CFS [<a href="#rid10">10</a>].</p><p>In resource-rich settings, studies have reported that approximately 10 to 25 percent of patients seen in primary care practices complain of chronic fatigue [<a href="#rid11">11,12</a>]. A similar population-based survey in India found that 12 percent of patients complained of fatigue for at least six months [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a>.)</p><p>CFS represents a very small subset of those who complain of chronic fatigue [<a href="#rid10">10,14</a>]. A random digit-dialing survey in Wichita, Kansas estimated the point prevalence of CFS to be 235 per 100,000; a one-year telephone survey follow-up among those not fatigued or fatigued for &lt;6 months found the incidence of CFS to be 180 per 100,000 [<a href="#rid15">15</a>]. Similar findings were noted in a prospective cohort study of over 4000 patients in a health maintenance organization; the estimated crude point prevalence of CFS ranged from 75 to 267 cases per 100,000 persons; the point prevalence of chronic fatigue not meeting the syndromic definition was strikingly higher, ranging from 1775 to 6321 cases per 100,000 persons [<a href="#rid14">14</a>]. Thus, even among patients with fatigue of at least six months' duration, the prevalence of CFS is well under 10 percent [<a href="#rid10">10,14</a>].</p><p>CFS is primarily a disorder of young to middle-aged adults, but cases in children have been recognized. It may also occur in older adults, although coexisting medical conditions usually preclude its consideration in this population. Most series report that CFS is about twice as common in women as in men [<a href="#rid16">16-18</a>]. While relatively fewer people from lower socioeconomic groups or minority populations seek care for this illness, a community-based study of nearly 17,000 people conducted by the United States Centers for Disease Control and Prevention (CDC) found that the prevalence of the illness was actually higher in such people [<a href="#rid19">19</a>]. Thus, the incidence in these groups may be underestimated due to their lack of equivalent access to health care institutions in which CFS is studied.</p><p>Cases of CFS usually arise in a sporadic manner, although closely related (if not identical) illnesses have occurred in outbreaks [<a href="#rid20">20-25</a>]. Other names for these types of outbreaks include epidemic neuromyasthenia and myalgic encephalomyelitis [<a href="#rid22">22,23</a>]. However, careful investigations of a putative "cluster" of CFS cases failed to reveal that there was a true epidemic [<a href="#rid24">24</a>].</p><p>Synthesizing all of the epidemiologic studies of CFS, the Institute of Medicine of the US National Academy of Sciences has estimated that there are between 836,000 and 2.5 million people in the United States with CFS, and that the direct and indirect economic costs of the illness range from USD $17 to 24 billion, annually [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H5"><span class="h1">PROPOSED ETIOLOGIES</span><span class="headingEndMark"> — </span>Considerable effort has gone into investigating possible causes of CFS. Among the many possible precipitants, the ones that have been most thoroughly studied are viruses, immune dysfunction, endocrine-metabolic dysfunction, and neuropsychiatric factors.</p><p class="headingAnchor" id="H6"><span class="h2">Infection</span><span class="headingEndMark"> — </span>There has been intense interest in whether certain viruses could be responsible for causing CFS, including Epstein-Barr virus (EBV), retroviruses, and others. No infectious agent has been proven to cause CFS. Nonetheless, many patients attribute their symptoms to a viral infection.</p><p class="headingAnchor" id="H88509117"><span class="h3">Viral infections</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus</strong> – EBV received a great deal of attention in the mid-1980s as a possible etiologic agent for CFS. This hypothesis was based upon three observations. First, EBV persists for life and reactivates frequently, thereby affording the virus the biologic potential for chronic illness. Second, patients with CFS were often found to possess higher than expected titers of antibodies to EBV capsid and early antigens, or to lack antibodies to EBV nuclear antigens (EBNA), each suggestive of recent or active infection. Third, some patients clearly attributed the onset of their illness to a mononucleosis-like infection. Several studies have documented that CFS can develop following a well-documented case of mononucleosis or primary EBV infection not producing full-blown mononucleosis [<a href="#rid26">26,27</a>]. Thus, primary infection with the virus appears capable of triggering the illness. However, there is no evidence that chronic EBV infection is responsible for ongoing, chronic symptoms.</p><p></p><p class="bulletIndent1">Most studies have found higher levels of certain antibodies to EBV antigens in patients with CFS compared with matched healthy control subjects. However, that does not prove a causal relationship. Indeed, one possible explanation is that the higher level of antibodies against EBV is an epiphenomenon reflecting subtle immune dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SARS-CoV-2</strong> – Some patients can develop post-coronavirus disease 2019 (COVID-19) conditions following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of illness severity. This has been referred to as "long-COVID," "post-COVID," "long-haul Covid," and other terms. </p><p></p><p class="bulletIndent1">Such patients present with a broad range of symptoms (physical and mental) that develop during or after COVID-19, continue for ≥3 months following the onset of illness, and are not explained by an alternative diagnosis [<a href="#rid28">28</a>]. There are probably a number of different mechanisms involved in the genesis of these clinical manifestations, including tissue damage from the infection as well as treatment, post-traumatic stress disorder (PTSD), and post-intensive care unit (ICU) syndrome. In addition, many patients with post-COVID-19 conditions fit the criteria for CFS with SARS-CoV-2 being the viral trigger. </p><p></p><p class="bulletIndent1">Post-COVID-19 symptoms are discussed in detail in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/129312.html" rel="external">"COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("Long COVID")"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retroviruses</strong> – Several studies reported finding evidence of novel exogenous retroviruses in patients with CFS [<a href="#rid29">29-31</a>]. However, subsequent studies have failed to confirm those reports [<a href="#rid32">32-34</a>], and several of the original reports have been retracted [<a href="#rid35">35,36</a>]. Another report failed to find that a human endogenous retrovirus (HERV) transcript, one that has been incriminated in other illnesses, was playing a role in CFS [<a href="#rid37">37</a>]. HERVs are ancient retroviruses that infected human germ line cells and became permanently integrated into the genome [<a href="#rid37">37</a>]. HERV genes are usually silenced but can become activated in response to viral infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other viruses</strong> – In addition to EBV, a number of other viruses have been proposed as a cause of CFS, although the published evidence is inconsistent. These include human herpesvirus type 6 (HHV-6), enteroviruses, Ross river virus, and Borna disease virus [<a href="#rid26">26,38</a>].</p><p></p><p class="headingAnchor" id="H3167656873"><span class="h3">Bacterial infections</span><span class="headingEndMark"> — </span>A syndrome similar to CFS has been reported following classical Lyme disease that has been promptly treated [<a href="#rid26">26,39</a>]. (See  <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults"</a>.)</p><p>A syndrome similar to CFS also has been reported following Q fever [<a href="#rid26">26,40</a>]. Further information regarding Q fever can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fqfever%2Fhealthcare-providers%2Findex.html&amp;token=JesNUNaJCNOJVQWCCy%2BywE9kqc5IU385wxveHccQyRSfy2l%2Fi1Nn583eHrl95FWC%2BYgb2SZ9DkIEVM4LBxkNAg%3D%3D&amp;TOPIC_ID=2740" target="_blank">United States Centers for Disease Control and Prevention website</a> [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H2922282647"><span class="h2">Immune system differences</span><span class="headingEndMark"> — </span>True immune deficiency is <strong>not</strong> a feature of this syndrome. Persons with CFS are not at increased risk for opportunistic infections. Some immunologic differences between persons with CFS and healthy controls have been reported, although their clinical significance is not yet clear.</p><p>The most frequently reported include depressed natural killer (NK) cell function [<a href="#rid43">43</a>], low levels of autoantibodies (often directed at targets in the nervous system) [<a href="#rid44">44</a>], increased numbers of activated CD8+ T cells [<a href="#rid45">45</a>], and increased levels of cytokines that correlate with CFS symptom severity [<a href="#rid46">46,47</a>]. A widely held hypothesis is that activation of the immune system in the brain leads to production of cytokines, and that the cytokines produce the symptoms of the illness [<a href="#rid48">48,49</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Endocrine-metabolic dysfunction</span><span class="headingEndMark"> — </span>A number of metabolic abnormalities have been described in CFS, but their causal role is unclear. Metabolic abnormalities that have been associated with CFS include:</p><p class="bulletIndent1"><span class="glyph">●</span>A hypometabolic state (akin to hibernation) [<a href="#rid50">50</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in the pathways converting sugars, lipids, and amino acids to energy [<a href="#rid51">51-53</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased serum cortisol and undersecretion of corticotropic-releasing hormone [<a href="#rid54">54</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Increased levels of insulin-like growth factor [<a href="#rid55">55</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in central nervous system serotoninergic activity [<a href="#rid56">56</a>]</p><p></p><p>However, some of these changes are not specific for CFS since similar neuroendocrine abnormalities are seen in patients with fibromyalgia [<a href="#rid57">57</a>], in other syndromes with atypical depressive features [<a href="#rid58">58</a>], and after an alteration in sleep pattern in otherwise healthy subjects [<a href="#rid59">59</a>]. Furthermore, some studies have not confirmed a defect in the pituitary-adrenal axis in patients with CFS [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Neurally mediated hypotension</span><span class="headingEndMark"> — </span>One study suggested that neurally mediated hypotension might play an important role in CFS symptoms. In this report, 23 subjects with CFS underwent tilt-table testing: 22 were found to have an abnormal test (compared with 4 of 14 unmatched controls) [<a href="#rid61">61</a>]. Those patients with a positive test were treated with escalating doses of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, and <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a>; almost all reported complete or partial resolution of symptoms. In a subsequent study of 600 patients with CFS from the same investigators, 77 percent of patients were found to have an abnormal tilt-table test [<a href="#rid62">62</a>]; however, no control group was mentioned.</p><p>A group from Israel developed a hemodynamic instability score in association with tilt testing and found that patients with CFS had positive scores or were unable to complete the test due to changes in blood pressure or heart rate, while patients with other conditions, such as chronic fatigue that did not meet CFS definitions, fibromyalgia, neurally mediated syncope, and familial hypertension, and otherwise healthy subjects, had negative scores [<a href="#rid63">63</a>]. The study was not blinded and control patients were not matched with CFS subjects.</p><p>Although these results appear intriguing, these early studies were not placebo-controlled, blinded, or randomized. A study in 21 pairs of monozygotic twins, in which one of the set had CFS and one did not, found abnormal tilt-table tests in 19 percent of those with CFS and 19 percent of those without [<a href="#rid64">64</a>]. In addition, a preliminary blinded study of 20 individuals with CFS who had not undergone tilt-table testing found that low-dose <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (0.1 to 0.2 mg) did not provide any benefit compared with placebo after six weeks of therapy [<a href="#rid65">65</a>]. Thus, the role of neurally mediated hypotension in CFS is unclear.</p><p class="headingAnchor" id="H10"><span class="h2">Depression</span><span class="headingEndMark"> — </span>The role of depression in CFS is controversial. Depression and anxiety are generally felt to occur as a consequence of CFS, although some studies have asserted that the fatigue results from depression [<a href="#rid26">26,66</a>]. </p><p>Three observational studies verified that two-thirds or more of patients with CFS met existing psychiatric criteria for anxiety disorders, dysthymia, or depression after becoming ill [<a href="#rid67">67-69</a>]; however, they did not determine what fraction of the patients had suffered from depression <strong>before</strong><em> </em>becoming ill with CFS. Even if depression is not the underlying cause but rather a consequence of CFS, it should be aggressively treated so that the patient can better manage CFS.</p><p class="headingAnchor" id="H22448877"><span class="h2">Sleep disruption</span><span class="headingEndMark"> — </span>Sleep disruption has been proposed as a possible cause of CFS. A small study showed that CFS patients had significant differences in polysomnographic findings and felt sleepier than controls after a night's sleep [<a href="#rid70">70</a>]. CFS patients had less total sleep time, lower sleep efficiency, and less rapid eye movement (REM) sleep than controls. The findings in the CFS group could neither be attributed to diagnosable sleep disorders nor to fibromyalgia.</p><p class="headingAnchor" id="H12"><span class="h2">Genetic studies</span><span class="headingEndMark"> — </span>Data generated from 227 patients with CFS who underwent detailed clinical evaluations, measurements of sleep physiology, cognitive function, autonomic nervous system function, and blood analyses of the sequence and expression of 20,000 genes have linked CFS to certain genes involved in immune and stress responses [<a href="#rid71">71,72</a>]. The following findings were noted in CFS patients compared with controls:</p><p class="bulletIndent1"><span class="glyph">●</span>Different levels of expression of genes with roles in the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system; functionally, these led to differences in how the body responds to hormones and other chemical messengers that are released in response to challenges and stressors, such as trauma, injury, and other adverse events [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DNA sequence changes in three genes associated with brain function, stress reactions, and emotional responses [<a href="#rid72">72</a>].</p><p></p><p>Additional studies have identified further potential genetic differences in persons with CFS when compared with asymptomatic controls [<a href="#rid73">73-75</a>]. These findings suggest the possibility that there is not a single cause of CFS, but that there may be a number of different stressors, physical and emotional, that could trigger the illness in those with a genetic predisposition. These studies are the strongest evidence for a biologic basis for CFS and may help to more effectively diagnose and develop effective treatments for this disease.</p><p class="headingAnchor" id="H13"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H165673839"><span class="h2">Common symptoms</span><span class="headingEndMark"> — </span>CFS is not a homogeneous disorder. Certain features are common to nearly all affected patients, while other subjective symptoms fluctuate with time but do not appear to progress  (<a class="graphic graphic_table graphicRef77546" href="/z/d/graphic/77546.html" rel="external">table 1</a>) [<a href="#rid16">16-18</a>].</p><p>Key clinical features include:</p><p class="bulletIndent1"><span class="glyph">●</span>Onset that may be sudden, often associated with a typical infection such as an upper respiratory infection or mononucleosis, or gradual over several months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overwhelming fatigue associated with additional symptoms (eg, altered sleep and cognition).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms characteristically exacerbated by excessive physical activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pre-CFS medical history that is not one of multiple somatic problems (eg, chronic backache or chronic headache). Affected patients are typically highly functioning individuals who are "struck down" with this disease. </p><p></p><p class="headingAnchor" id="H1350825663"><span class="h2">Examination findings</span><span class="headingEndMark"> — </span>Once the inciting illness (if any) is resolved, the physical examination typically is normal.</p><p class="bulletIndent1"><span class="glyph">●</span>Although patients commonly feel febrile, few ever demonstrate elevated temperatures).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Joints ache (arthralgia), but there are no objective signs of arthritis (ie, no erythema, effusion, or limitation of motion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the muscles are easily fatigued, strength is normal, as are biopsies and electromyograms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild cervical and/or axillary lymphadenitis is occasionally noted, and painful lymph nodes (lymphadenia) are a frequent complaint, but not true lymphadenopathy. Biopsied lymph nodes show only reactive hyperplasia. The cervical lymph nodes are involved most commonly, but the axillary lymph nodes may also be affected.</p><p></p><p>If the examination reveals objective abnormalities, such as inflamed joints, enlarged lymph nodes, or fever, these findings should be thoroughly evaluated to determine the cause. These findings are not consistent with CFS.</p><p>There is considerable overlap between CFS and fibromyalgia, and approximately 70 percent of patients with fibromyalgia also meet the criteria for CFS  (<a class="graphic graphic_table graphicRef138680" href="/z/d/graphic/138680.html" rel="external">table 2</a>) [<a href="#rid76">76,77</a>]. (See  <a class="medical medical_review" href="/z/d/html/5624.html" rel="external">"Clinical manifestations and diagnosis of fibromyalgia in adults"</a>.)</p><p>Many patients with CFS are partially or totally disabled by its manifestations. Some of these patients appear outwardly healthy, which may cause relatives and colleagues to accuse them of malingering. This can cause a vicious cycle of frustration, anger, and depression, compounded by the fact that their disabling symptoms are not visible to others. </p><p class="headingAnchor" id="H14"><span class="h2">CFS in pregnancy</span><span class="headingEndMark"> — </span>There is little published information about CFS in pregnancy. In a survey of 86 women who had 252 pregnancies before and after a diagnosis of CFS, approximately one-third of patients reported no change, one-third reported improvement, and one-third reported worsening of their symptoms both during and after pregnancy [<a href="#rid78">78</a>]. Pregnancy outcomes were similar before and after the onset of CFS when compared with a large Danish population-based survey. These data are limited by the nature of the survey, which relied on self-reporting, the lack of a healthy comparison group, and the somewhat low survey response rate (63 percent).</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS AND EVALUATION</span><span class="headingEndMark"> — </span>We use the 2015 Institute of Medicine (IOM) criteria to diagnose CFS  (<a class="graphic graphic_table graphicRef99875" href="/z/d/graphic/99875.html" rel="external">table 3</a>) [<a href="#rid9">9</a>]. Symptoms should be present for at least six months and have moderate, substantial, or severe intensity at least one-half of the time.</p><p>We obtain the following initial laboratory studies in patients with chronic fatigue:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential count</p><p class="bulletIndent1"><span class="glyph">●</span>Chemistries (including glucose, electrolytes, calcium, renal and hepatic function tests)</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid-stimulating hormone</p><p class="bulletIndent1"><span class="glyph">●</span>Creatine kinase (if muscle pain or weakness is present)</p><p></p><p>If the history or examination suggest sleep apnea, then we perform a sleep study. If the history or exam suggest adrenal insufficiency, then we evaluate for adrenal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a> and  <a class="medical medical_review" href="/z/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>.)</p><p>We do not perform routine neuroimaging. Magnetic resonance imaging (MRI) and single-photon emission computed tomography (SPECT) scan abnormalities seem to occur more frequently in patients with CFS than controls; however, these findings are of unknown significance and do not affect diagnosis or management [<a href="#rid79">79,80</a>].</p><p>The evaluation of the more general and common problem of chronic fatigue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue", section on 'Evaluation of chronic fatigue'</a>.)</p><p class="headingAnchor" id="H1422911551"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15916.html" rel="external">"Patient education: Myalgic encephalomyelitis/chronic fatigue syndrome (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4007.html" rel="external">"Patient education: Myalgic encephalomyelitis/chronic fatigue syndrome (Beyond the Basics)"</a>)</p><p></p><p>Additional information for patients with CFS and those caring for them can be obtained from the United States Centers for Disease Control and Prevention:</p><p>Centers for Disease Control and Prevention (CDC)</p><p>US Department of Health and Human Services</p><p>1600 Clifton Rd</p><p>Atlanta, GA 30329-4027</p><p>Telephone: 800-232-4636</p><p><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fme-cfs%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLFlbJnnbCwJ228MNU93WTC%2F72hPX07LqD9q60%2FwY0erd&amp;TOPIC_ID=2740" target="_blank">www.cdc.gov/cfs</a></p><p class="headingAnchor" id="H3329079726"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/132056.html" rel="external">"Patient perspective: Myalgic encephalomyelitis/chronic fatigue syndrome"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is an extremely debilitating illness of uncertain cause. While objective findings involving the central and autonomic nervous systems, the immune system, and energy metabolism have been described, these abnormalities have not yet led to a clear understanding of the pathophysiology of this condition or to a diagnostic test of adequate sensitivity and specificity. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – There are multiple case definitions for CFS, and these have changed over time. Using the Institute of Medicine (now the National Academy of Science) definition, symptoms should be present for at least six months and have moderate, substantial, or severe intensity at least one-half of the time. In addition to fatigue, other criteria include post-exertional malaise, unrefreshing sleep, cognitive impairment, and orthostatic-related symptoms. However, the strict application of this definition may not always be appropriate in the evaluation of a specific patient. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The US National Academy of Sciences has estimated that there are between 836,000 and 2.5 million people in the United States with CFS. CFS is primarily a disorder of young to middle-aged adults. It is about twice as common in women than in men. Of patients seeking medical care for this condition, relatively few are from minority or lower socioeconomic groups. However, the incidence in these groups may be underestimated due to more limited access to health care institutions in which CFS is studied. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proposed etiologies</strong> – Proposed etiologies for CFS include the following (see <a class="local">'Proposed etiologies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection – There has been intense interest in whether certain viruses could be responsible for causing CFS, including Epstein-Barr virus (EBV). None have been proven to cause CFS. (See <a class="local">'Infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immune dysfunction – CFS may be associated with mild immune dysregulation of uncertain pathogenetic importance. True immune deficiency is <strong>not</strong> a feature of this syndrome. (See <a class="local">'Immune system differences'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endocrine-metabolic dysfunction – Several metabolic abnormalities have been described in CFS, but their role in causing the symptoms of the illness is unclear. (See <a class="local">'Endocrine-metabolic dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Depression – Whether depression contributes to the development of CFS is controversial. Nonetheless, depression should be aggressively treated so that the patient can better manage CFS. (See <a class="local">'Depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – CFS is a severely debilitating illness of at least six months' duration that often starts suddenly (typically with an infectious-like illness) but can start more gradually as well. (See <a class="local">'Common symptoms'</a> above.)</p><p></p><p class="bulletIndent1">CFS is typically characterized by fatigue and: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Post-exertional malaise – A prolonged exacerbation of symptoms after physical, cognitive, or orthostatic exertion or stress</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unrefreshing sleep after sleeping many hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive impairment, exacerbated by exertion or stress</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Orthostatic intolerance – A worsening of symptoms after assuming or maintaining an upright posture, improved by recumbency</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other symptoms, as summarized in the table  (<a class="graphic graphic_table graphicRef77546" href="/z/d/graphic/77546.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1">The pre-CFS medical history of the patient is not one of multiple somatic problems such as chronic backache or chronic headache. Affected patients are typically highly functioning individuals who are "struck down" with this disease. (See <a class="local">'Common symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – There is no diagnostic test for CFS. The diagnosis is based upon history and physical examination findings that meet the 2015 Institute of Medicine (IOM) criteria  (<a class="graphic graphic_table graphicRef99875" href="/z/d/graphic/99875.html" rel="external">table 3</a>) and limited laboratory testing to exclude other causes of fatigue (see <a class="local">'Examination findings'</a> above and <a class="local">'Diagnosis and evaluation'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count with differential count</p><p class="bulletIndent2"><span class="glyph">•</span>Chemistry screen</p><p class="bulletIndent2"><span class="glyph">•</span>Thyroid-stimulating hormone level</p><p class="bulletIndent2"><span class="glyph">•</span>Creatine kinase (if muscle pain or weakness is present)</p><p class="bulletIndent2"><span class="glyph">•</span>Other tests when clinically indicated (see <a class="local">'Diagnosis and evaluation'</a> above)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367:346.</a></li><li class="breakAll">Aronowitz RA. From myalgic encephalitis to yuppie flu: A history of chronic fatigue syndromes. In: Framing Disease, Rosenberg CE, Golden J (Eds), Rutgers University Press, New Brunswick, NJ 1992.</li><li><a class="nounderline abstract_t">Kim E. A brief history of chronic fatigue syndrome. JAMA 1994; 272:1070.</a></li><li class="breakAll">Smith MEB, Nelson HD, Haney E, Pappas M, Daeges M, Wasson N, McDonagh M. Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Evidence Report/Technology Assessment No. 219. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 15-E001-EF. Rockville, MD: Agency for Healthcare Research and Quality; December 2014. www.effectivehealthcare.ahrq.gov/reports/final/cfm.</li><li><a class="nounderline abstract_t">Haney E, Smith ME, McDonagh M, et al. Diagnostic Methods for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:834.</a></li><li><a class="nounderline abstract_t">Green CR, Cowan P, Elk R, et al. National Institutes of Health Pathways to Prevention Workshop: Advancing the Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ann Intern Med 2015; 162:860.</a></li><li><a class="nounderline abstract_t">Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108:387.</a></li><li><a class="nounderline abstract_t">Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121:953.</a></li><li class="breakAll">IOM (Institute of Medicine). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press; 2015 http://www.iom.edu/mecfs (Accessed on February 12, 2015).</li><li><a class="nounderline abstract_t">Bates DW, Schmitt W, Buchwald D, et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 1993; 153:2759.</a></li><li><a class="nounderline abstract_t">Kroenke K, Wood DR, Mangelsdorff AD, et al. Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA 1988; 260:929.</a></li><li><a class="nounderline abstract_t">Wessely S, Chalder T, Hirsch S, et al. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. Am J Public Health 1997; 87:1449.</a></li><li><a class="nounderline abstract_t">Patel V, Kirkwood BR, Weiss H, et al. Chronic fatigue in developing countries: population based survey of women in India. BMJ 2005; 330:1190.</a></li><li><a class="nounderline abstract_t">Buchwald D, Umali P, Umali J, et al. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Ann Intern Med 1995; 123:81.</a></li><li><a class="nounderline abstract_t">Reyes M, Nisenbaum R, Hoaglin DC, et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med 2003; 163:1530.</a></li><li><a class="nounderline abstract_t">Jones JF, Ray CG, Minnich LL, et al. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 1985; 102:1.</a></li><li><a class="nounderline abstract_t">Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985; 102:7.</a></li><li><a class="nounderline abstract_t">Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988; 157:405.</a></li><li><a class="nounderline abstract_t">Steele L, Dobbins JG, Fukuda K, et al. The epidemiology of chronic fatigue in San Francisco. Am J Med 1998; 105:83S.</a></li><li class="breakAll">Gilliam AG. Epidemiologic study of an epidemic diagnosed as poliomyelitis, occurring among personnel of Los Angeles County General Hospital during the summer of 1934: Bull no 240. Institute of Health; US Public Health Service, Division of Infectious Diseases, Washington, DC 1938.</li><li><a class="nounderline abstract_t">ACHESON ED. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am J Med 1959; 26:569.</a></li><li><a class="nounderline abstract_t">HENDERSON DA, SHELOKOV A. Epidemic neuromyasthenia; clinical syndrome. N Engl J Med 1959; 260:757.</a></li><li><a class="nounderline abstract_t">AN OUTBREAK of encephalomyelitis in the Royal Free Hospital Group, London, in 1955. Br Med J 1957; 2:895.</a></li><li><a class="nounderline abstract_t">Levine PH, Dale JK, Benson-Grigg E, et al. A cluster of cases of chronic fatigue and chronic fatigue syndrome: clinical and immunologic studies. Clin Infect Dis 1996; 23:408.</a></li><li><a class="nounderline abstract_t">Holmes GP, Kaplan JE, Stewart JA, et al. A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? JAMA 1987; 257:2297.</a></li><li><a class="nounderline abstract_t">Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333:575.</a></li><li><a class="nounderline abstract_t">Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 2009; 124:189.</a></li><li class="breakAll">Post-COVID Conditions https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html (Accessed on July 13, 2021).</li><li><a class="nounderline abstract_t">DeFreitas E, Hilliard B, Cheney PR, et al. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci U S A 1991; 88:2922.</a></li><li><a class="nounderline abstract_t">Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326:585.</a></li><li><a class="nounderline abstract_t">Lo SC, Pripuzova N, Li B, et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A 2010; 107:15874.</a></li><li><a class="nounderline abstract_t">Henrich TJ, Li JZ, Felsenstein D, et al. Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis 2010; 202:1478.</a></li><li><a class="nounderline abstract_t">Alter HJ, Mikovits JA, Switzer WM, et al. A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. MBio 2012; 3.</a></li><li><a class="nounderline abstract_t">Simmons G, Glynn SA, Komaroff AL, et al. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011; 334:814.</a></li><li><a class="nounderline abstract_t">Silverman RH, Das Gupta J, Lombardi VC, et al. Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2011; 334:176.</a></li><li><a class="nounderline abstract_t">Lo SC, Pripuzova N, Li B, et al. Retraction for Lo et al., Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A 2012; 109:346.</a></li><li><a class="nounderline abstract_t">Oakes B, Hoagland-Henefield M, Komaroff AL, et al. Human endogenous retrovirus-K18 superantigen expression and human herpesvirus-6 and human herpesvirus-7 viral loads in chronic fatigue patients. Clin Infect Dis 2013; 56:1394.</a></li><li><a class="nounderline abstract_t">Working Group of the Royal Australasian College of Physicians. Chronic fatigue syndrome. Clinical practice guidelines--2002. Med J Aust 2002; 176 Suppl:S23.</a></li><li><a class="nounderline abstract_t">Coyle PK, Krupp LB, Doscher C, Amin K. Borrelia burgdorferi reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic. Clin Infect Dis 1994; 18 Suppl 1:S24.</a></li><li><a class="nounderline abstract_t">Wildman MJ, Smith EG, Groves J, et al. Chronic fatigue following infection by Coxiella burnetii (Q fever): ten-year follow-up of the 1989 UK outbreak cohort. QJM 2002; 95:527.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Q fever: Information for Healthcare Providers. Available at: https://www.cdc.gov/qfever/healthcare-providers/index.html. (Accessed on November 30, 2022).</li><li><a class="nounderline abstract_t">Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 2013; 62:1.</a></li><li><a class="nounderline abstract_t">Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139:3306.</a></li><li><a class="nounderline abstract_t">Loebel M, Grabowski P, Heidecke H, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun 2016; 52:32.</a></li><li><a class="nounderline abstract_t">Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28:1403.</a></li><li><a class="nounderline abstract_t">Montoya JG, Holmes TH, Anderson JN, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A 2017; 114:E7150.</a></li><li><a class="nounderline abstract_t">Hornig M, Montoya JG, Klimas NG, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 2015; 1.</a></li><li><a class="nounderline abstract_t">Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study. J Nucl Med 2014; 55:945.</a></li><li><a class="nounderline abstract_t">Hornig M, Gottschalk G, Peterson DL, et al. Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome. Mol Psychiatry 2016; 21:261.</a></li><li><a class="nounderline abstract_t">Naviaux RK, Naviaux JC, Li K, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci U S A 2016; 113:E5472.</a></li><li><a class="nounderline abstract_t">Fluge Ø, Mella O, Bruland O, et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight 2016; 1:e89376.</a></li><li><a class="nounderline abstract_t">Yamano E, Sugimoto M, Hirayama A, et al. Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles. Sci Rep 2016; 6:34990.</a></li><li><a class="nounderline abstract_t">Germain A, Ruppert D, Levine SM, Hanson MR. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biocyst 2107; 13:371.</a></li><li><a class="nounderline abstract_t">Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73:1224.</a></li><li><a class="nounderline abstract_t">Bennett AL, Mayes DM, Fagioli LR, et al. Somatomedin C (insulin-like growth factor I) levels in patients with chronic fatigue syndrome. J Psychiatr Res 1997; 31:91.</a></li><li><a class="nounderline abstract_t">Parker AJ, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med 2001; 31:1331.</a></li><li><a class="nounderline abstract_t">Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37:1583.</a></li><li><a class="nounderline abstract_t">Joseph-Vanderpool JR, Rosenthal NE, Chrousos GP, et al. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. J Clin Endocrinol Metab 1991; 72:1382.</a></li><li><a class="nounderline abstract_t">Leese G, Chattington P, Fraser W, et al. Short-term night-shift working mimics the pituitary-adrenocortical dysfunction in chronic fatigue syndrome. J Clin Endocrinol Metab 1996; 81:1867.</a></li><li><a class="nounderline abstract_t">Young AH, Sharpe M, Clements A, et al. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia). Biol Psychiatry 1998; 43:236.</a></li><li><a class="nounderline abstract_t">Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274:961.</a></li><li><a class="nounderline abstract_t">Rowe PC, Calkins H. Neurally mediated hypotension and chronic fatigue syndrome. Am J Med 1998; 105:15S.</a></li><li><a class="nounderline abstract_t">Naschitz JE, Rosner I, Rozenbaum M, et al. The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome. QJM 2003; 96:133.</a></li><li><a class="nounderline abstract_t">Poole J, Herrell R, Ashton S, et al. Results of isoproterenol tilt table testing in monozygotic twins discordant for chronic fatigue syndrome. Arch Intern Med 2000; 160:3461.</a></li><li><a class="nounderline abstract_t">Peterson PK, Pheley A, Schroeppel J, et al. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998; 158:908.</a></li><li><a class="nounderline abstract_t">Cope H, David A, Pelosi A, Mann A. Predictors of chronic "postviral" fatigue. Lancet 1994; 344:864.</a></li><li><a class="nounderline abstract_t">Taerk GS, Toner BB, Salit IE, et al. Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis). Int J Psychiatry Med 1987; 17:49.</a></li><li><a class="nounderline abstract_t">Kruesi MJ, Dale J, Straus SE. Psychiatric diagnoses in patients who have chronic fatigue syndrome. J Clin Psychiatry 1989; 50:53.</a></li><li><a class="nounderline abstract_t">Manu P, Lane TJ, Matthews DA. The frequency of the chronic fatigue syndrome in patients with symptoms of persistent fatigue. Ann Intern Med 1988; 109:554.</a></li><li><a class="nounderline abstract_t">Togo F, Natelson BH, Cherniack NS, et al. Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia. Arthritis Res Ther 2008; 10:R56.</a></li><li><a class="nounderline abstract_t">Smith AK, White PD, Aslakson E, et al. Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics 2006; 7:387.</a></li><li><a class="nounderline abstract_t">Goertzel BN, Pennachin C, de Souza Coelho L, et al. Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics 2006; 7:475.</a></li><li><a class="nounderline abstract_t">Schlauch KA, Khaiboullina SF, De Meirleir KL, et al. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome. Transl Psychiatry 2016; 6:e730.</a></li><li><a class="nounderline abstract_t">Nguyen CB, Alsøe L, Lindvall JM, et al. Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival. J Transl Med 2017; 15:102.</a></li><li><a class="nounderline abstract_t">Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016; 48:1564.</a></li><li><a class="nounderline abstract_t">Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 1994; 154:2049.</a></li><li><a class="nounderline abstract_t">Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160:221.</a></li><li><a class="nounderline abstract_t">Schacterle RS, Komaroff AL. A comparison of pregnancies that occur before and after the onset of chronic fatigue syndrome. Arch Intern Med 2004; 164:401.</a></li><li><a class="nounderline abstract_t">Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116:103.</a></li><li><a class="nounderline abstract_t">Schwartz RB, Garada BM, Komaroff AL, et al. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. AJR Am J Roentgenol 1994; 162:935.</a></li></ol></div><div id="topicVersionRevision">Topic 2740 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443043" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443043" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089894" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A brief history of chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089894" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A brief history of chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26075754" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnostic Methods for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26075757" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : National Institutes of Health Pathways to Prevention Workshop: Advancing the Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829679" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic fatigue syndrome: a working case definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978722" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978722" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257251" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence of fatigue and chronic fatigue syndrome in a primary care practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3398197" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314795" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870118" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic fatigue in developing countries: population based survey of women in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7778839" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860574" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2578266" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2578268" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2830340" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The chronic mononucleosis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790487" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The epidemiology of chronic fatigue in San Francisco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790487" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The epidemiology of chronic fatigue in San Francisco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13637100" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13644582" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epidemic neuromyasthenia; clinical syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13472002" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : AN OUTBREAK of encephalomyelitis in the Royal Free Hospital Group, London, in 1955.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842294" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A cluster of cases of chronic fatigue and chronic fatigue syndrome: clinical and immunologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3033337" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950834" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564299" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chronic fatigue syndrome after infectious mononucleosis in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564299" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Chronic fatigue syndrome after infectious mononucleosis in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1672770" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815723" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20798047" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20936980" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22991430" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940862" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998366" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22203980" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Retraction for Lo et al., Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408682" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Human endogenous retrovirus-K18 superantigen expression and human herpesvirus-6 and human herpesvirus-7 viral loads in chronic fatigue patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12056987" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Chronic fatigue syndrome. Clinical practice guidelines--2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8148448" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Borrelia burgdorferi reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145392" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chronic fatigue following infection by Coxiella burnetii (Q fever): ten-year follow-up of the 1989 UK outbreak cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145392" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chronic fatigue following infection by Coxiella burnetii (Q fever): ten-year follow-up of the 1989 UK outbreak cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535757" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2824604" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26399744" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antibodies toβadrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2166084" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunologic abnormalities in chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28760971" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cytokine signature associated with disease severity in chronic fatigue syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26079000" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Distinct plasma immune signatures in ME/CFS are present early in the course of illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24665088" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An¹¹C-(R)-PK11195 PET Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25824300" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27573827" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Metabolic features of chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28018972" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27725700" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1659582" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9201651" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Somatomedin C (insulin-like growth factor I) levels in patients with chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722149" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The neuroendocrinology of chronic fatigue syndrome and fibromyalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7980669" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1851185" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626849" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Short-term night-shift working mimics the pituitary-adrenocortical dysfunction in chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494707" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7674527" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The relationship between neurally mediated hypotension and the chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790477" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Neurally mediated hypotension and chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12589011" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112240" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Results of isoproterenol tilt table testing in monozygotic twins discordant for chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9570178" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7916407" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Predictors of chronic "postviral" fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3583562" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536690" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Psychiatric diagnoses in patients who have chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3421564" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The frequency of the chronic fatigue syndrome in patients with symptoms of persistent fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474105" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610949" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610957" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26859813" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28494812" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27749843" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092909" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10647761" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14980991" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A comparison of pregnancies that occur before and after the onset of chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1309285" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141020" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
